Ocular Toxoplasmosis

  • Daniel Vitor Vasconcelos-SantosEmail author
Part of the Essentials in Ophthalmology book series (ESSENTIALS)


Toxoplasmosis is a leading cause of infectious posterior uveitis worldwide. In immunocompetent individuals, systemic infection is usually subclinical. Ocular disease may be self-limited, presenting as retinochoroiditis, either early after primary infection or, more frequently, months or years later, by reactivation of latent retinal infection. Diagnosis of ocular toxoplasmosis is mainly clinical, based on typical presentation of focal necrotizing retinochoroiditis, often associated with adjacent chorioretinal scarring. Imaging modalities may be useful to delineate these posterior segment changes. Treatment is based on a combination of antiparasitic drugs and corticosteroids, the later to minimize possible sequelae of intraocular inflammation. Prognosis varies upon size/location of the lesion, as well as the local inflammatory process.


Ocular toxoplasmosis Retinochoroiditis Toxoplasma Toxoplasmose ocular Toxoplasma Retinochoroidite Uveíte Medicina tropical 


Conflict of Interest

The author declares that he does not have any conflict of interest.

No human studies were carried out by the author for this article.


  1. 1.
    Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363(9425):1965–76.PubMedCrossRefGoogle Scholar
  2. 2.
    Vasconcelos-Santos DV. Ocular manifestations of systemic disease: toxoplasmosis. Curr Opin Ophthalmol. 2012;23(6):543–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Holland GN. Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol. 2003;136(6):973–88.PubMedCrossRefGoogle Scholar
  4. 4.
    Oréfice F, Vasconcelos-Santos DV, Cordeiro CA, Oréfice JL, Costa RA. Toxoplasmosis. In: Foster CS, Vitale AT, editors. Diagnosis and treatment of uveitis. New Delhi: Jaypee-Highlights; 2013. p. 544–68.Google Scholar
  5. 5.
    Orefice JL, Costa RA, Scott IU, Calucci D, Orefice F, Grupo Mineiro de Pesquisa em Doencas Oculares I. Spectral optical coherence tomography findings in patients with ocular toxoplasmosis and active satellite lesions (MINAS report 1). Acta Ophthalmol. 2013;91(1):e41–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Dubey JP. The history and life cycle of Toxoplasma gondii. In: Weiss LM, Kim K, editors. Toxoplasma gondii – the model apicomplexan: perspectives and methods, vol. 2007. 1st ed. Amsterdam: Elsevier Academic Press; 2007. p. 1–17.Google Scholar
  7. 7.
    Dubey JP, Lago EG, Gennari SM, Su C, Jones JL. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology. 2012;139(11):1375–424.PubMedCrossRefGoogle Scholar
  8. 8.
    Bahia-Oliveira LM, Jones JL, Azevedo-Silva J, Alves CC, Orefice F, Addiss DG. Highly endemic, waterborne toxoplasmosis in North Rio de Janeiro state, Brazil. Emerg Infect Dis. 2003;9(1):55–62.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Vasconcelos-Santos DV, Azevedo DOM, Campos WR, Oréfice F, Queiroz-Andrade GM, Carellos EVM. Congenital toxoplasmosis in southeastern Brazil: results of early ophthalmologic examination of a large cohort of neonates. Ophthalmology. 2009;116(11):2199–205.e1.PubMedCrossRefGoogle Scholar
  10. 10.
    Peyron F, Wallon M, Kieffer F, Garweg JG. Toxoplasmosis. In: Wilson CB, Nizet V, Maldonado YA, Remington JS, Klein JO, editors. Remington and Klein’s infectious diseases of the fetus and newborn infant. 8th ed. Philadelphia: Saunders; 2016. p. 949–1042.Google Scholar
  11. 11.
    Dunn D, Wallon M, Peyron F, Petersen E, Peckham C, Gilbert R. Mother-to-child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999;353(9167):1829–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Silveira C, Belfort R Jr, Muccioli C, Abreu MT, Martins MC, Victora C, Nussenblatt RB, Holland GN. A follow-up study of Toxoplasma gondii infection in southern Brazil. Am J Ophthalmol. 2001;131(3):351–4.PubMedCrossRefGoogle Scholar
  13. 13.
    Arantes TE, Silveira C, Holland GN, Muccioli C, Yu F, Jones JL, Goldhardt R, Lewis KG, Belfort R Jr. Ocular involvement following postnatally acquired Toxoplasma gondii infection in Southern Brazil: a 28-year experience. Am J Ophthalmol. 2015;159(6):1002–1012.e1002.PubMedCrossRefGoogle Scholar
  14. 14.
    Pavesio CE, Lightman S. Toxoplasma gondii and ocular toxoplasmosis: pathogenesis. Br J Ophthalmol. 1996;80(12):1099–107.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Bhopale GM. Pathogenesis of toxoplasmosis. Comp Immunol Microbiol Infect Dis. 2003;26(4):213–22.PubMedCrossRefGoogle Scholar
  16. 16.
    Saeij JP, Boyle JP, Boothroyd JC. Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host. Trends Parasitol. 2005;21(10):476–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Pena HF, Gennari SM, Dubey JP, Su C. Population structure and mouse-virulence of Toxoplasma gondii in Brazil. Int J Parasitol. 2008;38(5):561–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Bottos J, Miller RH, Belfort RN, Macedo AC, Belfort R Jr, Grigg ME. Bilateral retinochoroiditis caused by an atypical strain of Toxoplasma gondii. Br J Ophthalmol. 2009;93(11):1546–50.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Carneiro AC, Andrade GM, Costa JG, Pinheiro BV, Vasconcelos-Santos DV, Ferreira AM, Su C, Januario JN, Vitor RW. Genetic characterization of Toxoplasma gondii revealed highly diverse genotypes for isolates from newborns with congenital toxoplasmosis in southeastern Brazil. J Clin Microbiol. 2013;51(3):901–7.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Silva LA, Reis-Cunha JL, Bartholomeu DC, Vitor RW. Genetic polymorphisms and phenotypic profiles of sulfadiazine-resistant and sensitive Toxoplasma gondii isolates obtained from newborns with congenital toxoplasmosis in Minas Gerais, Brazil. PLoS One. 2017;12(1):e0170689.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol. 2004;137(1):1–17.PubMedGoogle Scholar
  22. 22.
    Mets MB, Holfels E, Boyer KM, Swisher CN, Roizen N, Stein L, Stein M, Hopkins J, Withers S, Mack D, Luciano R, Patel D, Remington JS, Meier P, McLeod R. Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol. 1997;123(1):1–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Demar M, Hommel D, Djossou F, Peneau C, Boukhari R, Louvel D, Bourbigot AM, Nasser V, Ajzenberg D, Darde ML, Carme B. Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana. Clin Microbiol Infect. 2012;18(7):E221–31.PubMedCrossRefGoogle Scholar
  24. 24.
    Bowen LN, Smith B, Reich D, Quezado M, Nath A. HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nat Rev Neurol. 2016;12(11):662–74.PubMedCrossRefGoogle Scholar
  25. 25.
    Balasundaram MB, Andavar R, Palaniswamy M, Venkatapathy N. Outbreak of acquired ocular toxoplasmosis involving 248 patients. Arch Ophthalmol. 2010;128(1):28–32.PubMedCrossRefGoogle Scholar
  26. 26.
    Oréfice F, Bahia-Oliveira LM. Toxoplasmose. In: Oréfice F, editor. Uveíte clínica e cirúrgica. Rio de Janeiro: Cultura Médica; 2005. p. 699–804.Google Scholar
  27. 27.
    Smith JR, Cunningham ET Jr. Atypical presentations of ocular toxoplasmosis. Curr Opin Ophthalmol. 2002;13(6):387–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Holland GN, Muccioli C, Silveira C, Weisz JM, Belfort R Jr, O’Connor GR. Intraocular inflammatory reactions without focal necrotizing retinochoroiditis in patients with acquired systemic toxoplasmosis. Am J Ophthalmol. 1999;128(4):413–20.PubMedCrossRefGoogle Scholar
  29. 29.
    Garweg JG, de Groot-Mijnes JD, Montoya JG. Diagnostic approach to ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19(4):255–61.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Montoya JG. Laboratory diagnosis of Toxoplasma gondii infection and toxoplasmosis. J Infect Dis. 2002;185(Suppl 1):S73–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Montoya JG, Parmley S, Liesenfeld O, Jaffe GJ, Remington JS. Use of the polymerase chain reaction for diagnosis of ocular toxoplasmosis. Ophthalmology. 1999;106(8):1554–63.PubMedCrossRefGoogle Scholar
  32. 32.
    Vasconcelos-Santos DV, Andrade GM, Caiaffa WT. Zika virus, microcephaly, and ocular findings. JAMA Ophthalmol. 2016;134(8):946.PubMedCrossRefGoogle Scholar
  33. 33.
    Vasconcelos-Santos DV, Dodds EM, Orefice F. Review for disease of the year: differential diagnosis of ocular toxoplasmosis. Ocul Immunol Inflamm. 2011;19(3):171–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Morais FB, Arantes TE, Muccioli C. Current practices in ocular toxoplasmosis: a survey of Brazilian uveitis specialists. Ocul Immunol Inflamm. 2018;26(2):317–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Kim SJ, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS, Recchia FM. Interventions for toxoplasma retinochoroiditis: a report by the American Academy of ophthalmology. Ophthalmology. 2013;120(2):371–8. Scholar
  36. 36.
    Petersen E. Toxoplasmosis. Semin Fetal Neonatal Med. 2007;12(3):214–23.PubMedCrossRefGoogle Scholar
  37. 37.
    Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, Yaseri M, Peyman GA. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118(1):134–41.PubMedCrossRefGoogle Scholar
  38. 38.
    Heringer GC, Oueghlani E, Dell’Omo R, Curi AL, Orefice F, Pavesio CE. Risk of reactivation of toxoplasmic retinitis following intraocular procedures without the use of prophylactic therapy. Br J Ophthalmol. 2014;98(9):1218–20.PubMedCrossRefGoogle Scholar
  39. 39.
    Orefice JL, Costa RA, Orefice F, Campos W, da Costa-Lima D Jr, Scott IU. Vitreoretinal morphology in active ocular toxoplasmosis: a prospective study by optical coherence tomography. Br J Ophthalmol. 2007;91(6):773–80.PubMedCrossRefGoogle Scholar
  40. 40.
    Silveira C, Belfort R Jr, Muccioli C, Holland GN, Victora CG, Horta BL, Yu F, Nussenblatt RB. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134(1):41–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Fernandes Felix JP, Cavalcanti Lira RP, Cosimo AB, Cardeal da Costa RL, Nascimento MA, Leite Arieta CE. Trimethoprim-sulfamethoxazole versus placebo in reducing the risk of toxoplasmic retinochoroiditis recurrences: a three-year follow-up. Am J Ophthalmol. 2016;170:176–82.PubMedCrossRefGoogle Scholar
  42. 42.
    Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109(5):869–78.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Universidade Federal de Minas Gerais, Faculdade de MedicinaBelo HorizonteBrazil

Personalised recommendations